3 results
Part I (dose-escalation): to evaluate the safety of SYD985 and to determine the Maximum Tolerated Dose and Recommended Phase 2 DosePart II (expanded cohorts): to evaluate the Objective tumour Response Rate
Primary objectives:• To evaluate the effect of orvepitant once daily on cough severity, as perceived by patients, with IPF• To evaluate the safety of orvepitant once daily in patients with IPFSecondary objectives:• To evaluate the effect of…
The primary objective of this study is to demonstrate that SYD985 is superior to physician*s choice in prolonging progression-free survival (PFS) on the basis of the blinded independent central review of tumour assessment.The secondary objectives of…